

References

I-112

1. Ruff P, Cutsem EV, Lakomy R, et al. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. *J Geriatr Oncol*. 2018;9(1):32-39.
2. Cutsem EV, Joulian F, Hoff PM, et al. Aflibercept plus FOLFIRI vs. placebo plus FOLFIRI in second-line metastatic colorectal cancer: A post hoc analysis of survival from the phase III VELOUR study subsequent to exclusion of patients who had 6 Months of completing adjuvant oxaliplatin-based therapy. *Target Oncol*. 2016;11(3):383-400.
3. Ivanonva JI, Saverno KR, Sung J, et al. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA. *Med Oncol*. 2017;34(193):1-10.
4. Strickler JH, Rushing CN, Niedzwiecki D, et al. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. *BMC Cancer*. 2019;19(1):1-9.
5. Muro K, Salinardi T, Singh AR, et al. Safety of aflibercept in metastatic colorectal cancer: A literature review and expert perspective on clinical and real-world data. *Cancers (Basel)*. 2020;12(4):844.
6. Cleary JM, Horick NK, McCleary NJ, et al. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. *Cancer*. 2019;125(13):2213-2221.
7. Buchler T, Kiss I, Hornova J, et al. Sequential treatment with bevacizumab and aflibercept for metastatic colorectal cancer in real-world clinical practice. *Target Oncol*. 2020;15(2):193-201.
8. Ziv-aflibercept In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated April 6, 2016.
9. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Ziv-Aflibercept.
10. Micromedex DrugDex Compendium®. 2024. Ziv-aflibercept (Zaltrap).
11. National Comprehensive Cancer Network (NCCN). Ziv-aflibercept. NCCN Drugs and Biologics Compendium®. 2024.
12. Zaltrap® (ziv-aflibercept) injection, for intravenous use [package insert]. Sanofi-Aventis. U.S. LLC. Bridgewater, NJ. Revised 12/2020.